Sign in Subscribe
Health care industry

TYSABRI Demonstrates Significant Efficacy in Two-Year Multiple Sclerosis Study

Strategic Insights

— 1 min read

Patients treated with TYSABRI, a monoclonal antibody, experienced a significant reduction in disability progression and clinical relapses in a two-year study. The AFFIRM Phase III trial, presented at the American Academy of Neurology meeting, showed that TYSABRI reduced the risk of disability progression by 42% and clinical relapses by 67% compared to placebo. Additionally, MRI analysis revealed sustained and statistically significant reductions in the number and volume of brain lesions. The study's findings confirm the efficacy of TYSABRI in managing multiple sclerosis and highlight its potential as a treatment option for patients with relapsing forms of the disease.

Key Takeaways:

  • TYSABRI significantly reduced disability progression by 42% and clinical relapses by 67% compared to placebo over two years.
  • The two-year data from the AFFIRM Phase III trial confirmed the efficacy of TYSABRI in reducing disability progression and clinical relapses in patients with relapsing forms of multiple sclerosis.
  • MRI analysis revealed sustained and statistically significant reductions in the number and volume of brain lesions in patients treated with TYSABRI.
  • The study's findings highlight the potential of TYSABRI as a treatment option for patients with relapsing forms of multiple sclerosis.
  • Patients in the study were randomized to receive either a 300 mg IV infusion dose of TYSABRI or placebo every four weeks.
  • The risk of disability progression was reduced by 54% with TYSABRI treatment using a pre-defined sensitivity analysis.

Statistics:

  • 42% reduction in the risk of disability progression compared to placebo (p = 0.0002)
  • 67% reduction in the rate of clinical relapses relative to placebo (p = 0.0001)
  • 54% reduction in the risk of disability progression using a pre-defined sensitivity analysis (p = 0.0001)
  • 29% of placebo-treated patients had progressed after two years, while only 17% of TYSABRI-treated patients had progressed
  • 41% reduction in the proportion of patients progressing (p = 0.0001)

Sources:

  • Business Wire
  • American Academy of Neurology
  • Biogen Idec
  • Elan Corporation, plc
  • February 28, 2005: Biogen Idec and Elan Corporation, plc voluntary suspension of TYSABRI from the U.S. market and all ongoing clinical trials

Read more